Navigation Links
Genetic variant mimics effect of heart failure medications

A genetic variation, found predominantly in African Americans, protects some people with heart failure, enabling them to live longer than expected. Thats the conclusion of a research team led by investigators at the University of Maryland School of Medicine in Baltimore and the Washington University School of Medicine in St. Louis. The researchers found that the genetic variation acts just like beta-blockers, a class of drugs used to treat chronic heart failure. Study results will be available in the online version of Nature Medicine (, on April 20, 2008.

In the study, the researchers found that African American heart failure patients with the genetic variation had a natural protection against death and the need for a heart transplant that is the same as the protection provided by beta-blocker therapy. Those patients who were given beta-blockers did not experience additional benefits from the medications because their own genetic beta blockade was already protecting them.

The researchers say their discovery adds to the accumulating evidence that genetic differences contribute to the way people respond to medications, and should encourage the use of genetic testing in clinical trials to identify people who can benefit from therapy tailored to their personal genetic makeup. This is a significant development in our understanding of why some African American patients appear to not respond to beta-blockers in the same way as Caucasian patients, says one of the studys co-authors, Stephen B. Liggett, M.D., professor of medicine and physiology at the University of Maryland School of Medicine and director of its cardiopulmonary genomics program. In this case, it seems that this genetic variation is a good thing, mimicking drugs that are frequently used to treat heart failure, says Dr. Liggett.

Heart failure refers to the hearts inability to pump adequate amounts of blood through the body. Heart failure can be the result of hypertension or a heart attack. In some cases, called idiopathic cardiomyopathy, the cause is not identified. As heart failure progresses, adrenalin produces a fight or flight response to stimulate the heart into action by binding to receptors on heart cells called beta-adrenergic receptors. Over time, this attempt to enhance pumping in the diseased heart causes it to enlarge, change shape, and become even less effective as a pump.

In some patients, beta-blockers allow the heart to get some relief from the overactive pumping, develop a more normal cellular structure, and shrink in size. They do this by blocking or toning down the fight or flight response. Beta-blockers are a standard, highly effective therapy in some, but not all, patients with heart failure and ischemia, a cardiac blood flow disorder. But among African Americans, for unclear reasons, beta-blockers have had variable success.

To unravel this mystery, the researchers looked for human genetic variants in two types of genes associated with cardiac function, GRK2 and GRK5. These act as natural brakes to hold down overactive beta receptors. The researchers thought variants in these genes might modify the risk or outcome of heart failure, or alter the response to heart failure therapy. Nothing unusual came out of their search of the GRK2 gene.

However, in GRK5, they discovered a genetic variant. This was accomplished by taking genetic profiles of more than 2,000 volunteers in Cincinnati, Kansas City and Atlanta, including Americans of European descent and African Americans. Some of the volunteers had heart failure; others had ischemia; healthy volunteers made up a third group.

To deepen their understanding of the genetic variation, the researchers created cell lines and developed genetically altered mice to predict how the gene would function in humans. They discovered that the genetic variant acts in a way that is identical to beta-blocker drugs, reducing the impact of adrenalin that forces the heart to work harder. In an experimental model, the variant protected the mice from developing heart failure after exposure to a substance similar to adrenaline.

Armed with this information, they launched a prospective study of 375 African Americans with heart failure at the University of Cincinnati and followed them for an average of two-and-a-half years. Some were on one of the two commonly used beta-blockers in the United States (carvedilol or metoprolol); others were not on beta-blockers. While the presence of the variant did not prevent the onset of heart failure, those with the variant who had heart failure were just as protected as those without the variant who were on beta-blockers.

The researchers say this particular genetic variant occurred in about 40 percent of African Americans they studied. The variant also occurs in about two percent of Caucasians. While it is likely to be a factor in those patients as well, a much larger study would be required to verify this, because the variant is so uncommon.

For several years, a controversy has existed in the cardiovascular field because of conflicting reports about whether beta-blockers helped African-American patients, says co-author Gerald W. Dorn II, M.D., professor of medicine, associate chairman for translational research and director of the Center for Pharmacogenomics at Washington University. By mimicking the effect of beta-blockers, the genetic variant makes it appear as if beta blockers arent effective in these patients.

According to Dr. Liggett, the discovery of this variant is another milestone on the road to personalized medicine. In heart failure treatment, there is still a lot of one drug fits all thinking. This variant is one of what may be many genetic variants that can be used like a scorecard to guide treatment in a much more personalized way, says Dr. Liggett. He adds that the University of Maryland School of Medicine has multiple research studies underway to further identify by genetic means which patients should be treated with which drugs.


Contact: Bill Seiler
University of Maryland Medical Center

Related biology news :

1. Does the desire to consume alcohol and tobacco come from our genetic makeup?
2. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
3. Many parents at-risk for cancer disclose genetic test results to children
4. Genetics determine optimal drug dose of common anticoagulant
5. Claims of sex-related differences in genetic association studies often not properly validated
6. American College of Medical Genetics responds to new FDA labeling decision for warfarin
7. UNC study questions FDA genetic-screening guidelines for cancer drug
8. Genome study shines light on genetic link to height
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
11. Rutgers Genetics receives $7.8 million for autism research
Post Your Comments:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is ... it is bound to proteins, copper is also toxic to cells. With a ... Polytechnic Institute (WPI) will conduct a systematic study of copper in the bacteria ...
(Date:11/24/2015)... ... , ... This fall, global software solutions leader SAP and AdVenture Capital brought ... pitch their BIG ideas to improve health and wellness in their schools. , Now, ... the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl 50, ...
Breaking Biology Technology: